Bausch Health Companies Inc. (BHC)

NYSE: BHC · Real-Time Price · USD
7.24
+0.03 (0.35%)
Sep 10, 2025, 11:06 AM - Market open
0.35%
Market Cap2.68B
Revenue (ttm)9.86B
Net Income (ttm)98.00M
Shares Out 369.80M
EPS (ttm)0.27
PE Ratio27.43
Forward PE1.48
Dividendn/a
Ex-Dividend Daten/a
Volume258,212
Open7.19
Previous Close7.21
Day's Range7.19 - 7.32
52-Week Range4.25 - 9.85
Beta0.48
AnalystsHold
Price Target9.00 (+24.4%)
Earnings DateOct 29, 2025

About BHC

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern... [Read more]

Sector Healthcare
CEO Thomas Appio
Employees 20,700
Stock Exchange NYSE
Ticker Symbol BHC
Full Company Profile

Financial Performance

In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for BHC stock is "Hold." The 12-month stock price target is $9.0, which is an increase of 24.40% from the latest price.

Price Target
$9.0
(24.40% upside)
Analyst Consensus: Hold
Stock Forecasts

News

Bausch + Lomb Announces Publication of Data From a Prospective Study Evaluating the Efficacy of XIIDRA® in Alleviating Discomfort in Symptomatic Contact Lens Wearers

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Clinical Ophth...

1 day ago - Business Wire

Bausch Health's Aesthetic Business, Solta Medical, Surpasses Milestone of 5 Million Skin Tightening Treatments with Thermage(R) Non-Surgical System

LAVAL, QC / ACCESS Newswire / September 5, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and Solta Medical, a global leader in the medical aest...

5 days ago - Accesswire

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

LAVAL, QC AND CUPERTINO, CA / ACCESS Newswire / August 26, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, and DURECT Corporation (NASDAQ:DRRX) t...

Other symbols: DRRX
15 days ago - Accesswire

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that...

20 days ago - Accesswire

Bausch + Lomb board members resign after Icahn agreement ends

Bausch + Lomb said on Monday Brett Icahn and Gary Hu have resigned from its board of directors after the termination of the agreement with billionaire Carl Icahn and some of his affiliates.

22 days ago - Reuters

Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes

LAVAL, QC / ACCESS Newswire / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulson Capital Inc. and certain affiliates and...

25 days ago - Accesswire

Why Bausch Health Stock Surged By Nearly 20%

Bausch Health surged by nearly 20% on high volume on Monday, rebounding from a post-earnings sell-off driven by high risk and debt concerns. Q2 results beat revenue and GAAP EPS estimates, with strong...

4 weeks ago - Seeking Alpha

Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners

For the Sixth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship   LAVAL, QC / ACCESS Newswire / August 7, 2025 / Bausch Health Companies Inc. (NYSE:BH...

4 weeks ago - Accesswire

Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript

Bausch Health Companies Inc. (NYSE:BHC) Q2 2025 Earnings Conference Call July 30, 2025 5:00 PM ET Company Participants Garen Sarafian - VP & Head of Investor Relations Jean-Jacques Charhon - Executiv...

5 weeks ago - Seeking Alpha

Bausch Health Announces Second Quarter 2025 Results

Second Quarter Consolidated Revenues of $2.53 billion, up 5% on a Reported basis and 4% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health Compani...

5 weeks ago - Accesswire

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

Bausch Health Companies Inc. BHC on Tuesday agreed to indirectly acquire DURECT Corp DRRX, including a novel therapeutic molecule, larsucosterol.

Other symbols: DRRX
6 weeks ago - Benzinga

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option for the treatment of patients with al...

Other symbols: DRRX
6 weeks ago - Accesswire

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Ophthalmology ...

6 weeks ago - Business Wire

Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand

LAVAL, QC / ACCESS Newswire / July 28, 2025 / Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company") today announced that its subsidiary, Bausch Health Americas, Inc., h...

6 weeks ago - Accesswire

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

LAVAL, QC / ACCESS Newswire / July 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Michael Goettler and Sa...

6 weeks ago - Accesswire

CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs

This press release updates the headline of the previously posted release LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:B...

2 months ago - Accesswire

Bausch Health Appoints New Chief Accounting Officer

LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Steven Lee as Senior Vi...

2 months ago - Accesswire

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs

LAVAL, QC / ACCESS Newswire / July 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene an...

2 months ago - Accesswire

Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence

Focused on highlighting real patient experiences, Salix continues to lead the charge in educating and advocating for the hepatic encephalopathy community LAVAL, QC / ACCESS Newswire / July 7, 2025 / B...

2 months ago - Accesswire

Bausch Health to Announce Second Quarter 2025 Results on July 30

LAVAL, QC / ACCESS Newswire / July 2, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Bausch ...

2 months ago - Accesswire

Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live bet...

2 months ago - Business Wire

A Billionaire Trump Supporter Is Buying These Two Stocks

John Paulson, former hedge-fund manager, bought large blocks of Bausch Health and Perpetua Resources through funds.

Other symbols: PPTA
2 months ago - Barrons

Bausch Health Shares Rise as Nonexecutive Chairperson Paulson Buys $21.2M in Shares

Bausch Health shares rose Wednesday morning after a director made a substantial purchase of company stocks.

3 months ago - Market Watch

Repricing Potential Driven By Deleveraging

Bausch Health is significantly undervalued, trading at depressed multiples due to high debt and patent risk, but its core business remains stable and cash generative. Recent refinancing has extended d...

3 months ago - Seeking Alpha

Bausch + Lomb Launches Blink® Nourish Lubricating Eye Drops and Blink Boost Lubricating Eye Drops in the United States

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launc...

3 months ago - Business Wire